NCT00981162View on ClinicalTrials.gov

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2012

Conditions
Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

sorafenib tosylate

Given PO

DRUG

everolimus

Given PO

OTHER

laboratory biomarker analysis

Correlative study

OTHER

pharmacogenomic studies

Correlative study

OTHER

pharmacological study

Correlative study

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

80045

University of Colorado at Denver Health Sciences Center, Aurora

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER